The technology developed by Amarantus has multiple development opportunities. As such, the Company intends to partner product development with leading academic institutions, research institutes, hospitals, clinics, small to large scale biotechnology, pharmaceutical, diagnostic and device companies to achieve maximum value creation for its high-value, multi-purposed discoveries. Amarantus is interested in partnering opportunities for its product candidates that will allow development of adjunct -products that will address diseases caused by poorly served biological pathways.
Amarantus and Banyan Biomarkers have collaborated to evaluate MANF’s potential as a disease-modifying agent for the treatment of Traumatic Brain Injury.
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. Banyan Biomarkers has a licensing agreement with the University of Florida for exclusive global use of technology related to this product. To learn more about Banyan Biomarkers, Inc., visit http://www.banyanbio.com.
Memory Dx, LLC
Memory Dx, LLC, (formerly Provista Life Sciences) is a privately-held company that owns the intellectual property rights to the LymPro Alzheimer’s Disease Diagnostic Blood Test. Amarantus entered into a licensing agreement with Memory Dx, LLC for the LymPro Alzheimer’s Disease Diagnostic Blood Test in December 2012.